← All indications
Myocardial Infarction
NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION).
Subtype terms (6)
More specific conditions that are subtypes of Myocardial Infarction in the MeSH hierarchy.
- Anterior Wall Myocardial Infarction
12 drugs (6 approved, 6 experimental)
- Inferior Wall Myocardial Infarction
1 drug approved
- MINOCA
6 drugs approved
- Non-ST Elevated Myocardial Infarction
28 drugs (27 approved, 1 experimental)
- Shock, Cardiogenic
36 drugs (24 approved, 12 experimental)
- ST Elevation Myocardial Infarction
102 drugs (71 approved, 31 experimental)
Drugs by status
Approved for this indication (47)
- ramipril
- hydrochlorothiazide
- prasugrel
- eplerenone
- evolocumab
- spironolactone
- warfarin
- telmisartan
- lisinopril
- ticagrelor
- oxygen
- cangrelor
- alteplase
- perindopril
- valsartan
- sitagliptin
- olmesartan
- acetylsalicylic acid
- carvedilol
- thallous chloride ti 201
- niacin
- candesartan
- enoxaparin
- staphylokinase
- nadolol
- clopidogrel
- amlodipine
- doxazosin
- simvastatin
- pyrophosphoric acid
- +17 more
Phase 4 trials (87)
- fondaparinux sodium
- folic acid
- bivalirudin
- henagliflozin
- pitavastatin
- streptozotocin
- pioglitazone
- rubidium chloride rb-82
- inactivated influenza vaccine
- rosuvastatin
- edaravone
- icosapent ethyl
- sodium chloride
- acetylcysteine
- famotidine
- bilberry
- bezafibrate
- sevoflurane
- alirocumab
- abciximab
- salvianolate
- diltiazem
- isosorbide
- suxiao jiuxin
- etanercept
- vericiguat
- semaglutide
- ezetimibe
- fentanyl
- danhong
- +57 more
Phase 3 trials (71)
- mlc1501
- stem cells
- sotalol
- furosemide
- Lumbricus rubellus
- propafenone
- vitamin e
- chlorthalidone
- procainamide
- metformin
- imipramine
- whole blood
- edetic acid
- autologous bone marrow derived mesenchymal cells
- ticlopidine
- cyclosporine
- autologous mononuclear stem cell
- eculizumab
- autologous mesenchymal stem cells
- doxycycline
- ziltivekimab
- lerodalcibep
- omega-3 fatty acids
- sodium nitrite
- quinidine
- ferumoxides
- gelatin
- anakinra
- corn
- darbepoetin alfa
- +41 more
Phase 2 trials (76)
- tolerogenic dendritic cells
- bone marrow derived mononuclear cells
- allogeneic cardiosphere-derived cells
- autologous human c-kit cscs ii
- orticumab
- alprazolam
- elinogrel
- autologous cd34+ cells
- peripheral blood lymphocytes
- nesiritide
- delcasertib
- albumin (Human)
- cyclophosphamide
- autologous cd133+ stem cells
- naltrexone
- sodium thiosulfate
- opl-0301
- coumarin
- methoxy polyethylene glycol-epoetin beta
- SP16
- hydroxyethyl starch
- mangafodipir trisodium
- Zalunfiban
- nivolumab
- exosomes from mesenchymal stem cells
- firibastat
- spermidine
- apolipoprotein
- cardiac stem cells
- liraglutide
- +46 more
Phase 1 trials (21)
- midazolam
- ventrigel
- misaver
- chimeric natriuretic peptide
- autologous umbilical cord blood
- ts23
- gadobenate
- revacept
- autologous skeletal myoblast
- 18f dpa-714
- autologous cardiac stem cells
- np-011
- bone marrow derived autologous cd34+ selected cells
- typhoid vi polysaccharide vaccine
- dextrose
- Dapansutrile
- nx-cp105
- fludeoxyglucose f-18
- vegf-d gene transfer
- autologous adipose-derived mesenchymal stem cells
- deferiprone
Other trials (34)
- ethanol
- sufonylurea
- gelidium elegans
- proline
- arthrospira platensis
- troponin
- ubiquinone
- esmolol
- oat
- everolimus
- arginine
- propofol
- Desmoteplase
- curcumin
- ferumoxytol
- 18f-2-fluoro-2-deoxy-d-glucose fluorodeoxyglucose
- c-21
- glucagon-like peptide-1
- motexafin gadolinium
- genistein
- efaproxiral
- qiliqiangxin
- 68ga-nodaga-rgd
- selenium
- cow milk
- voglibose
- lysine
- ferrous sulfate
- sodium bicarbonate
- piperine
- +4 more
Organizations
Organization Involved with Phase 4 Indications (237)
- Lytics
- Kyungpook University
- Osaka Acute Coronary Insufficiency Study Group
- Noordwest Ziekenhuisgroep
- Chinese Center of Diseases Control and Prevention
- Government of China
- Nanjing Medical University
- University of Campania Luigi Vanvitelli
- Federal University of Rio Grande do Sul
- Department of Veteran Affairs
- Aarne Koskelo Foundation
- Region Zealand
- University of Oxford
- A.R. CARD Onlus Foundation
- Inha University
- SHF Svendborg
- Erasmus University Rotterdam
- University of Modena and Reggio Emilia
- Guangzhou Recomgen Biotech Co., Ltd.
- University of Helsinki
- Byrraju Foundation
- Silesian University of Medicine
- Swedish Heart Lung Foundation
- Shanghai Xuhui District Central Hospital
- Charles University
- B. Braun
- Kyoto Prefectural University of Medicine
- Government of Czech Republic
- Orion Corporation
- The North Denmark Region
- +207 more
Organization Involved with Phase 3 Indications (214)
- Hospital Universitario Virgen Macarena
- Suzhou Landing Pharmaceuticals
- Government of Mexico
- Norwegian Heart and Lung Patient Organisation
- Centers for Disease Control and Prevention (CDC)
- Atlantic Health System
- University of Ulm
- Humboldt University
- University of Leipzig
- University of Massachusetts
- HEINZ NIXDORF-FOUNDATION
- Johnson and Johnson
- University of Rochester
- New England Research Institutes
- Wake Forest University
- Chinese People's Armed Police Forces
- Abbott
- ARTTIC International Management Services
- Linkoping University
- Vall d'Hebron Institute of Research, Galatea Clinic
- Georgetown University
- Hospital Alessandro Manzoni Lecco
- Roche
- Medical University of Graz
- Royan Institute
- Texas Tech University
- University of South Carolina
- Dartmouth University
- State University of New York
- University of Heidelberg
- +184 more
Organization Involved with Phase 2 Indications (118)
- Dr. Sami Ulus Children's Hospital
- University of Turin
- Fundación Canaria Rafael Clavijo para la Investigación Biomédica
- Faraday Pharmaceuticals, Inc.
- Hacettepe University
- Summa Health System
- CSL Behring
- Polyphor Ltd.
- Azienda Ospedaliera San Gerardo di Monza
- Mercy Gilbert Medical Center
- Biopure Corporation
- Lee's Pharmaceutical
- Okayama University
- Sorbonne University
- Bhagwan Mahaveer Jain Hospital
- The Interuniversity Cardiology Institute of the Netherlands
- Portola Pharmaceuticals
- ATIGEN-CELL
- CardioCell LLC
- TargeGen
- University of Texas, Galveston
- University of Ankara
- University of Western Ontario
- LG
- Ablynx
- Armaron Bio Pty Ltd
- South-Eastern Norway Regional Health Authority
- Papworth Hospital NHS Foundation Trust
- Yuksek Ihtisas University
- Caladrius Biosciences
- +88 more
Organization Involved with Phase 1 Indications (20)
- ABX-CRO
- Shanghai Life Science & Technology
- Healthcare Discoveries Inc.
- Angiotech Pharmaceuticals
- AdvanceCor GmbH
- Minneapolis Heart Institute
- Kuopio University Hospital
- University of Eastern Finland
- Government of Japan
- Texas Heart Institute
- Translational Sciences, Inc.
- Honya Medical Inc
- Chung Shan Medical University
- Badalona Hospital Germans Trias i Pujol
- Ever Supreme Bio Technology Co., Ltd.
- Sakakibara Heart Institute
- Garnet BioTherapeutics, Inc.
- PPD
- Procorde GmbH
- Ventrix, Inc.
Organization Involved with Other Experimental Indications (58)
- The First People's Hospital of Xinmi
- The Peoples' Hospital of Jiaozuo City
- The Second People's Hospital of Pingdingshan
- Henan Medical University
- National Cerebral and Cardiovascular Center
- Shenma Medical Group General Hospital
- The second people's Hospital of Jiyuan
- Nanyang Central Hospital
- Yanshi People’s Hospital
- Keesler Medical Center
- Xinyang Central Hospital
- Vanderbilt University
- Chalmers University of Technology
- Henan University of Traditional Chinese Medicine
- Region Västmanland
- AORTICA Group
- University of Tromso
- The First People's Hospital of Zhumadian
- Puyang Oil Field General Hospital
- University of Salamanca
- Yellow River Sanmenxia hospital
- University of Manitoba
- RWTH Aachen University
- Providence Health & Services
- Canadian Anesthesiologists' Society
- Japan Cardiovascular Research Foundation
- Toujinkai Hospital
- The Young Investigator Group of Cardiovascular Research
- University of Grenoble
- Kaifeng Central Hospital
- +28 more